



EY Entrepreneur of the year-2013



FROST & SULLIVAN
2013 BEST PRACTICES AWARD
Competitive Strategy Leadership Award, India



Business today/YES bank
Excellence Awards-2013



8th September 2017

To

National Stock Exchange of India Ltd.

Exchange Plaza, Plot No. C/1, G-Block,
Bandra-Kurla Complex, Bandra (E), Mumbai

Kind Attn: Mr. Kautuk Upadhyay, Manager

Ref No.: NSE/LIST/18456 Dated: 07-Sep-2017

Sub: Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

We refer to the contents of your above referred letter and clarify the matter as under:

1. Our Company has been listed on the National Stock Exchange of India Limited and the BSE Limited for the first time on 29th June 2017 ("**Listing Date**");
2. Being an unlisted entity prior to the Listing Date, we were neither required to prepare nor publish the quarterly financial results in respect of any period prior to the Listing Date. You may appreciate that the requirement of preparation and publication of the quarterly financial results typically applies to the listed entities only in terms of the Securities and Exchange Board Of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**LODR**");

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN
2013 BEST PRACTICES AWARD
Competitive Strategy Leadership Award, India



Business today/YES bank
Excellence Awards-2013



3. The quarterly financial results of our company in respect of the quarter April-June 2017 (“**Reporting Period Results**”) are prepared as per IND-AS and have been duly approved by the Board of Directors of our Company (“**Board**”) and has also been duly subjected to the limited review of our Statutory Auditors before its eventual publication, in terms of the requirements of the LODR;
4. The comparative quarterly financial results in respect of the quarter April-June 2016 (“**Comparative Period Results**”) have also been prepared and published as per IND-AS only and have similarly undergone the respective scrutiny of the Board as is applicable to the Reporting Period Results under the LODR.
5. Based on our aforesaid submissions, you may kindly appreciate that the Comparative Period Results were never prepared or published as per IND-GAAP. Hence, these Comparative Period Results are not and have never been at variance with any of our previously reported results. Therefore, in our view, no reconciliation is necessary nor desirable and should best be avoided in the interest of maintaining clarity about the reported figures as both are already based on IND-AS and are, even otherwise, compliant with LODR.

We believe that we have been able to resolve the raised query to your complete satisfaction. We are available to answer any further queries that you may have in this regard.

Yours truly,

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar

Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867